Genzyme Corp. has encountered a manufacturing problem during the fill/finish stage of production of Thyrogen at its Allston, MA plant. As a result, a shortage of the thyroid medicine for Fabry’s disease is expected. The problem led to the rejection of a single lot of the drug because of a quality issue. Genzyme plans to fill and finish all future lots of Fabrazyme at a contract manufacturing facility operated by Hospira Inc., which already handles a large portion of Fabrazyme’s fill/finish. L...